Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does REBOXETINE Cause Therapeutic product effect incomplete? 14 Reports in FDA Database

Sharpen Your Memory & Focus Naturally

NeuroZoom — 35 clinically studied ingredients. No stimulants. Pure brain support.

Boost Your Brain

According to the FDA Adverse Event Reporting System (FAERS), 14 reports of Therapeutic product effect incomplete have been filed in association with REBOXETINE. This represents 7.6% of all adverse event reports for REBOXETINE.

14
Reports of Therapeutic product effect incomplete with REBOXETINE
7.6%
of all REBOXETINE reports
0
Deaths
0
Hospitalizations

How Dangerous Is Therapeutic product effect incomplete From REBOXETINE?

Of the 14 reports, and 1 (7.1%) were considered life-threatening.

Is Therapeutic product effect incomplete Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for REBOXETINE. However, 14 reports have been filed with the FAERS database.

What Other Side Effects Does REBOXETINE Cause?

Hyperhidrosis (21) Off label use (20) Weight increased (18) Tachycardia (17) Confusional state (16) Intentional overdose (16) Nausea (16) Drug ineffective (15) Drug interaction (15) Sleep disorder (15)

What Other Drugs Cause Therapeutic product effect incomplete?

ALBUTEROL (8,496) ADALIMUMAB (6,986) PREDNISONE (6,709) METHOTREXATE (6,037) TOFACITINIB (4,914) SECUKINUMAB (4,661) BUDESONIDE\FORMOTEROL (4,392) TIOTROPIUM (4,327) MEPOLIZUMAB (4,106) ETANERCEPT (3,961)

Which REBOXETINE Alternatives Have Lower Therapeutic product effect incomplete Risk?

REBOXETINE vs RECLAST REBOXETINE vs RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E REBOXETINE vs REGADENOSON REBOXETINE vs REGORAFENIB REBOXETINE vs REGORAFENIB\REGORAFENIB

Related Pages

REBOXETINE Full Profile All Therapeutic product effect incomplete Reports All Drugs Causing Therapeutic product effect incomplete REBOXETINE Demographics